Innate immune response induced by gene delivery vectors.

Gene therapy is a clinical strategy that has the potential to treat an array of genetic and nongenetic diseases. Vectors for gene transfer are the essential tools of gene therapy. For gene therapy to be successful, an appropriate amount of the therapeutic gene must be delivered into the target cells without substantial toxicity. A major limitation of the use of gene therapy vectors is the innate immune responses triggered by systemic administration of such vectors. It is essential to overcome vector-mediated innate immune responses, such as production of inflammatory cytokines, the maturation of antigen-presenting cells and tissue damage, because the induction of these responses not only shortens the period of gene expression but also leads to serious side effects. Viral vectors (for example, adenovirus (Ad) vectors) have been assumed to be more potent in inducing innate immune responses in spite of their high transduction efficiency since they contain pathogenic proteins. However, recent studies have demonstrated that not only viral vectors but also nonviral vectors, such as lipoplex (liposome/plasmid DNA complex), can induce innate immune responses. Indeed, nonviral vectors including lipoplex induce comparable or larger levels of innate immune response than viral vectors. In this review, we present an overview of the innate immune responses induced by Ad vector and lipoplex, which are used primarily for in vivo gene transfer.

[1]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[2]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[3]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[4]  J. Wilson,et al.  Adenoviruses as gene-delivery vehicles. , 1996, The New England journal of medicine.

[5]  C. Férec,et al.  Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. , 2001, Human gene therapy.

[6]  G. Prud’homme DNA vaccination against tumors , 2005, The journal of gene medicine.

[7]  J. Wilson,et al.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[9]  H. Mizuguchi,et al.  Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector , 2003, Gene Therapy.

[10]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[11]  Shizuo Akira,et al.  Innate immune recognition of viral infection , 2006, Nature Immunology.

[12]  S. Akira,et al.  Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  A. Gaggar,et al.  Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.

[14]  D. Palmer,et al.  Helper-dependent adenoviral vectors for gene therapy. , 2005, Human gene therapy.

[15]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[16]  D. Liggitt,et al.  Cationic Liposome-mediated Intravenous Gene Delivery (*) , 1995, The Journal of Biological Chemistry.

[17]  H. Mizuguchi,et al.  Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. , 2006, Human gene therapy.

[18]  D. Muruve,et al.  The innate immune response to adenovirus vectors. , 2004, Human gene therapy.

[19]  M. Kaleko,et al.  Development of adenovirus serotype 35 as a gene transfer vector. , 2003, Virology.

[20]  C. Coban,et al.  A Toll-like receptor–independent antiviral response induced by double-stranded B-form DNA , 2006, Nature Immunology.

[21]  A. Kiang,et al.  Adenovirus Infection Triggers a Rapid, MyD88-Regulated Transcriptome Response Critical to Acute-Phase and Adaptive Immune Responses In Vivo , 2006, Journal of Virology.

[22]  B. Berkhout,et al.  Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5 , 2004, Journal of Virology.

[23]  A. Parker,et al.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.

[24]  M. Imperiale,et al.  Promoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expression , 1997 .

[25]  T. Libermann,et al.  Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. , 2002, Human gene therapy.

[26]  D. Collen,et al.  Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. , 2005, Human gene therapy.

[27]  Meredith O'Keeffe,et al.  Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9‐dependent maturation and IFN‐α production , 2006, The journal of gene medicine.

[28]  M. Hashida,et al.  Use of lipoplex‐induced nuclear factor‐κB activation to enhance transgene expression by lipoplex in mouse lung , 2006, The journal of gene medicine.

[29]  M. Hashida,et al.  Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model , 2003, Cancer Gene Therapy.

[30]  J. Marshall,et al.  Improved Cationic Lipid Formulations for In Vivo Gene Therapy , 1995, Annals of the New York Academy of Sciences.

[31]  K. Matsushima,et al.  Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs , 2005, The Journal of experimental medicine.

[32]  Y. Takakura,et al.  Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9‐dependent and ‐independent pathways , 2005, Journal of leukocyte biology.

[33]  K. Matsushima,et al.  Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. , 2004, International immunology.

[34]  P. Colarusso,et al.  The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. , 2003, Human Gene Therapy.

[35]  H. Mizuguchi,et al.  Reduction of Natural Adenovirus Tropism to Mouse Liverby Fiber-Shaft Exchange in Combination with both CAR- andαv Integrin-BindingAblation , 2003, Journal of Virology.

[36]  Qiang Liu,et al.  Akt/Protein Kinase B Activation by Adenovirus Vectors Contributes to NFκB-Dependent CXCL10 Expression , 2005, Journal of Virology.

[37]  J. Wilson,et al.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  M. Kay,et al.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors , 1997, Journal of virology.

[39]  R. M. Burnett,et al.  Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.

[40]  S. Ni,et al.  Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors , 2004, Journal of Virology.

[41]  T. Libermann,et al.  Adenovirus Vector-Induced Expression of the C-X-C Chemokine IP-10 Is Mediated through Capsid-Dependent Activation of NF-κB , 2000, Journal of Virology.

[42]  M. Hashida,et al.  The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes , 2002, Gene Therapy.

[43]  E. P. Black,et al.  Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. , 2007, Virology.

[44]  N. Philpott,et al.  Influence of Fiber Detargeting on Adenovirus-Mediated Innate and Adaptive Immune Activation , 2005, Journal of Virology.

[45]  M. Hollenberg,et al.  Activation of p38 and ERK Signaling during Adenovirus Vector Cell Entry Lead to Expression of the C-X-C Chemokine IP-10 , 2002, Journal of Virology.

[46]  H. Ertl,et al.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.

[47]  L. Stamatatos,et al.  Increased Level and Longevity of Protective Immune Responses Induced by DNA Vaccine Expressing the HIV-1 Env Glycoprotein when Combined with IL-21 and IL-15 Gene Delivery1 , 2006, The Journal of Immunology.

[48]  A. Thomson,et al.  Recombinant Adenovirus Induces Maturation of Dendritic Cells via an NF-κB-Dependent Pathway , 2000, Journal of Virology.

[49]  C. Johansson,et al.  Adenoviruses Use Lactoferrin as a Bridge for CAR-Independent Binding to and Infection of Epithelial Cells , 2006, Journal of Virology.

[50]  Simon C Watkins,et al.  Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[51]  Feng Liu,et al.  Development of non-viral vectors for systemic gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[52]  D. Liggitt,et al.  Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  A. Kiang,et al.  Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  H. Mizuguchi,et al.  Approaches to improving the kinetics of adenovirus-delivered genes and gene products. , 2005, Advanced drug delivery reviews.

[55]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[56]  R. Scheule The role of CpG motifs in immunostimulation and gene therapy. , 2000, Advanced drug delivery reviews.

[57]  U. Greber,et al.  Adenovirus‐activated PKA and p38/MAPK pathways boost microtubule‐mediated nuclear targeting of virus , 2001, The EMBO journal.

[58]  T. Eggerman,et al.  Rapid Kupffer cell death after intravenous injection of adenovirus vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  D. Liggitt,et al.  Systemic gene expression after intravenous DNA delivery into adult mice. , 1993, Science.

[60]  P. Sova,et al.  Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting , 2006, Cancer Gene Therapy.

[61]  T. Niidome,et al.  Gene Therapy Progress and Prospects: Nonviral vectors , 2002, Gene Therapy.

[62]  B. Assael,et al.  Interaction of Adenovirus Type 5 Fiber with the Coxsackievirus and Adenovirus Receptor Activates Inflammatory Response in Human Respiratory Cells , 2006, Journal of Virology.

[63]  Feng Liu,et al.  Non‐immunostimulatory nonviral vectors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  H. Mizuguchi,et al.  Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. , 2007, Human gene therapy.

[65]  C. Densmore,et al.  Pulmonary cytokine responses associated with PEI–DNA aerosol gene therapy , 2001, Gene Therapy.

[66]  I. Kovesdi,et al.  Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression , 1997, Journal of virology.

[67]  S. Nakagawa,et al.  Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[68]  H. Mizuguchi,et al.  Fiber-Modified Adenovirus Vectors Decrease Liver Toxicity through Reduced IL-6 Production1 , 2007, The Journal of Immunology.

[69]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[71]  Leaf Huang,et al.  LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth , 1999, Gene Therapy.

[72]  S. Kawakami,et al.  Intracellular distribution of NFκB decoy and its inhibitory effect on TNFα production by LPS stimulated RAW 264.7 cells , 2005 .